drugset / Trial / NCT02475564

Resveratrol for Pain Due to Endometriosis

NCT02475564 ↗

Phase 4 Completed 44 enrolled Hospital de Clinicas de Porto Alegre
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to verify whether the use of 40 mg of resveratrol per day associated with monophasic contraceptive pill (levonorgestrel 0.15mg/ethinyl estradiol 0.03mg) reduces pelvic pain at the end of 2 months of treatment, compared to the use of the pill with placebo.

Timeline

Start
2015-06
Primary completion
2015-11
Completion
2015-11

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Resveratrol vs Placebo; p = 0.7; Mann-Whitney test NCT02475564 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 40 mg —

Indications